Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00361959
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2006-08-07
Brief Title:
SERETIDE 50500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Multicentre Randomised Double-Blind Double Dummy Parallel Group 104-week Study to Compare the Effect of the SalmeterolFluticasone Propionate Combination Product SERETIDE 50500mcg Delivered Twice Daily Via the DISKUSACCUHALER Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease COPD
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a comparator study to assess the relative efficacy of the combination product fluticasone propionatesalmeterol 50500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease COPD over a two year study interval
Detailed Description:
A Multicentre Randomised Double-Blind Double Dummy Parallel Group 104 Week Study to Compare the Effect of the SalmeterolFluticasone Propionate Combination Product SERETIDE 50500mcg with Tiotropium Bromide 18 mcg on the Rate of Exacerbations in Subjects with Severe Chronic Obstructive Pulmonary Disease COPD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None